Indivior-backed survey finds 58% of U.S. correctional facilities offer at least one FDA-approved MOUD

Indivior reported results from a cross-sectional survey published in the Journal of Correctional Health Care assessing access to medications for opioid use disorder (MOUD) in U.S. correctional facilities. The study, conducted with the National Commission on Correctional Health Care, surveyed 212 jails, prisons, and detention centers and found that 58% offered at least one FDA-approved MOUD. The survey found that jails were more than twice as likely as prisons to provide MOUD, and facilities in the West had more than triple the odds of offering MOUD compared with those in the Midwest. Respondents cited implementation barriers including stigma, abstinence-only approaches, limited provider training, and constrained budgets. Qualitative feedback highlighted needs for reentry support such as housing, care coordination, and expanded use of long-acting injectables and telehealth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603171201PRIMZONEFULLFEED1001170683) on March 17, 2026, and is solely responsible for the information contained therein.